Why I believe investing in these FTSE 100 dividend stocks could make you a millionaire retiree

Royston Wild discusses two dynamic dividend stocks from the FTSE 100 (INDEXFTSE: UKX) that could make you richer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

sdf

Even though Big Pharma has continued to be racked with the impact of colossal patent expirations, investors for the large part seem to be pretty unconcerned.

Take AstraZeneca (LSE: AZN), for example. Its share price has ballooned by more than 80% over the past five years even as the loss of exclusivity on revenue drivers like Crestor has pounded the bottom line.

Quite why the market remains upbeat isn’t a secret. Sure, a return to significant earnings growth may not have been achieved as early as many had been expecting. But the hard yards that the FTSE 100 firm has been putting in on the R&D front is finally starting to pay off.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

The raft of product approvals over the past half a decade helped the sale of new medicines like Lynparza and Fasenra barge through the $1bn barrier in the first half of 2018. Even though the business has endured some development setbacks in recent years, the strength of its lab teams has still laid the groundwork for sales to rip higher once more.

Profits set to rebound

The rapid progression of AstraZeneca’s recently-launched products, and the encouraging progress seen across its bulging pipeline, clearly give plenty of reason to expect profits to explode sooner rather than later. The emphasis the firm’s putting on emerging markets gives me further grounds for optimism too.

Between January and June, sales to these developing regions rose 14% year-on-year, underpinned by exceptional medicines demand in China where AstraZeneca’s revenues leapt 33%. Sales were helped by the launch of lung cancer battler Tagrisso too, a product which drove total oncology product sales in the Chinese marketplace 57% higher from the same 2017 period.

City analysts expect the company to burst back into growth with a 12% rise in 2019. They may also be expecting dividends to remain frozen at 280 US cents per share through to then — a figure that yields a chubby, inflation-busting 3.7%, incidentally — but I’m confident that having turned the corner, dividends should follow profits higher again.

At current prices, AstraZeneca sports a forward P/E ratio of 22.5 times. Heady on paper, sure, but a figure that I still consider a snip given the rate at which the firm’s new medicines are flying off the shelves.

Testing titan

Intertek Group (LSE: ITRK) is another Footsie firm I believe contains millionaire-maker investment potential.

The inspection and product testing giant has a terrific record of lifting dividends and City analysts are not expecting the trend to end any time soon. Last year’s 71.3p per share payout is predicted to rise to 96p in 2018 and to 106.2p in the following 12-month period.

Subsequent yields of 2.1% and 2.4% for these years may not be anything to write home about. However, Intertek’s bright growth outlook (the City is anticipating further annual profits improvements of 1% this year and 9% next year), assisted by its insatiable appetite for acquisitions, mean that dividends should keep ripping higher for some time to come.

And this makes it one of the hottest income stocks on the FTSE 100, in my opinion. I’d happily buy Intertek alongside AstraZeneca despite its similarly-high paper valuation, a forward P/E multiple of 22.9 times, as the possibility of creating a million-dollar portfolio — along with some other choice stocks from the Footsie — with both or either is too good to miss.


Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Intertek. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

With a 4.7% yield (as well as being potentially 77% undervalued) is this income stock a no-brainer buy?

Our writer’s found an income stock that looks to be undervalued. Surely this ideal combination makes it a Strong Buy?…

Read more »

Group of friends meet up in a pub
Investing Articles

How much do you need in an ISA to target a £5,000 monthly passive income?

Discover how making regular investments into the stock market can mushroom into a sizeable passive income portfolio over time.

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

Meet the FTSE 100 juggernaut that’s smashing Nvidia shares in 2025! 

Rolls-Royce (LON:RR) has done it yet again, and the shares were on the move in the FTSE 100 today. But…

Read more »

Close-up of a woman holding modern polymer ten, twenty and fifty pound notes.
Investing Articles

Can the British American Tobacco dividend keep growing?

Christopher Ruane explains why he retains faith in the potential for ongoing British American Tobacco dividend growth, despite shrinking cigarette…

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

After Shell announced another huge buyback, are its shares undervalued?

Andrew Mackie looks at the long-term case for owning Shell shares, which are up 150% in 5 years and accelerating…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

Here’s why Unilever could be a dividend share to consider right now

The Unilever dividend yield isn't one of the biggest, but a lacklustre share price performance is making it look potentially…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 FTSE 250 value stocks to consider buying while they’re hated

The UK market may be enjoying its time in the sun but Paul Summers thinks he's found two interesting value…

Read more »

Investing Articles

Up 15% in July! Is this FTSE 100 dividend growth superstar the best share to buy in August?

Harvey Jones is looking for the best share to buy over the next month. This blue-chip has been lavishing investors…

Read more »